Evidence map›Paper›PMID 42067617›Full record

ReviewExperimental & molecular medicine2026

Spatiotemporal precision interventions for cardiac repair and regenerative therapy.

Mei Hua Ting, Huipeng Zhang, Siyuan Liu, Peng Wang, Hongjun Li, Wenbin Zhang, Junbo Ge, Ning Zhang

Abstract readReview
In one paragraph

Review in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mei Hua Ting *Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0009-0000-1526-5173
Huipeng Zhang *State Key Laboratory of Advanced Drug Delivery and Release Systems, Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, Liangzhu Laboratory, School of Pharmacy, Zhejiang University, Hangzhou, China.
Siyuan Liu *Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Peng WangDepartment of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hongjun LiState Key Laboratory of Advanced Drug Delivery and Release Systems, Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, Liangzhu Laboratory, School of Pharmacy, Zhejiang University, Hangzhou, China. hongjun@zju.edu.cn.ORCID http://orcid.org/0000-0002-1765-8445
Wenbin ZhangDepartment of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. 3313011@zju.edu.cn.ORCID http://orcid.org/0000-0003-4746-9570
Junbo GeDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China. jbge@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-9360-7332
Ning ZhangDepartment of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. NingZhang17@126.com.ORCID http://orcid.org/0000-0001-6628-3953

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82270262National Natural Science Foundation of China (National Science Foundation of China) 82300565
6 · The paper itself

Abstract

Restoring cardiac function after myocardial infarction remains a major challenge, as current pharmacological and interventional therapies primarily mitigate symptoms and slow disease progression without addressing the irreversible loss of functional myocardium. Although a diverse range of biologically active agents has been developed to modulate inflammation, angiogenesis, fibrosis, and cardiomyocyte survival, their therapeutic impact is frequently limited by delivery strategies that fail to match the dynamic and heterogeneous nature of post-infarction healing. Advances in biomaterials, nanotechnology, and device engineering have enabled drug delivery systems capable of spatiotemporally programmed therapeutic engagement. By responding to injury-associated cues, recreating key features of the myocardial microenvironment, and incorporating programmable release architectures, these systems coordinate localization, release kinetics, and duration of action with distinct phases and regions of cardiac repair. When combined with appropriate delivery interfaces, including nanocarriers, injectable depots, structured platforms, and biologically derived vehicles, spatiotemporal drug delivery transforms therapy from passive administration into an active determinant of biological outcome. This Review synthesizes recent mechanistic and engineering advances to frame spatiotemporal precision as a unifying principle for cardiac drug delivery. Aligning therapeutic action with the intrinsic biology of myocardial healing provides a rational pathway toward more effective, durable, and biologically informed strategies for cardiac repair and, where biology permits, regeneration.

Indexed as

HeartMyocardial InfarctionRegenerationRegenerative MedicineAnimalsDrug Delivery SystemsHumansMyocardium

Identifiers

PMID42067617
PMCPMC13234137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.